drugset / Trial / NCT02075528
Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Phase 4
Completed
41 enrolled
Taipei City Hospital
Johnson & Johnson Taiwan Ltd · collabTaipei Institute of Pathology · collab
NaSingle-groupOpen-labelTreatment
Summary
Paliperidone ER is a new psychotropic medication for schizophrenia treatment. The studies of 6-week acute treatment and 52-week maintenance treatment showed positive results in patients with schizophrenia and its clinical improvement may start at Day 4. Some second-generation antipsychotics have been found that using the first 2 weeks' treatment results to predict the fourth or sixth week's treatment response is acceptable. The primary aim of this study is to investigate: 1. . whether the early prediction model used in other atypicals could also be applied in paliperidone ER. 2. . The changes of metabolic parameters and pharmacokinetics after paliperidone ER treatment in this study
Timeline
- Start
- 2009-07
- Primary completion
- 2012-05
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 9 mg | — |